Heart Failure, Congestive Clinical Trial
Official title:
Enhancing Caregiver Support for Patients With Heart Failure
Informal caregivers, assisted by health information technology may help to fill the gaps in VA care management of heart failure patients by enhancing support for patients' treatment adherence, behavior changes, and symptom monitoring.
Background: Heart failure (HF) is a leading cause of preventable hospitalization and death
in the VA and many patients fall short of self-care goals. Numerous efficacy trials have
shown that HF care management supported by health information technology (i.e., HITCM) can
improve patients' outcomes, although VA care managers in 'real-world' health systems are
often overwhelmed by the need to provide monitoring and behavior change services. Informal
caregivers may help to fill the gaps in VA care management and enhance support for patients'
treatment adherence, behavior changes, and symptom monitoring. The challenge will be to
identify ways to leverage assistance from informal caregivers (ICGs) who lack the resources
to fill this role effectively.
Objectives: We will evaluate the impact of extending the reach of HITCM by incorporating a
protocol-driven model for improved monitoring and self-management support by a CarePartner
(CP). CPs will be adult children or friends living outside the patient's home who are
willing to play a structured role to support self-care. The specific aims of the trial are:
(1) to determine whether an intervention that uses automated patient monitoring and behavior
change calls with follow-up to HF patients' care manager and CP (HITCM+CP) improves key
patient-centered outcomes relative to a system that only uses the same technology to support
patients' care management (HITCM-only). Outcomes of interest include patients'
health-related quality of life, mental health, health service use, and mortality risk; (2)
to evaluate the impact of HITCM+CP on patients' self-care behaviors compared to HITCM-only;
and (3) to determine whether the intervention increases the quality and quantity of support
for HF patients' self-care compared to HITCM-only.
Methods: 372 HF patient-CP pairs will be recruited from the VA Louis Stokes (Cleveland)
Healthcare System. Patients will receive automated telephone assessment and behavior change
calls weekly for 12 months. For patients in both study arms, a care manager will monitor
patients' assessment results via a secure website and will receive reports concerning urgent
health problems by fax and pager. In the HITCM+CP group, patients' CPs also will receive
tailored e-mail reports based on patients' weekly assessments. HITCM+CP patients and their
CPs will use a structured protocol to review the patient's assessment results, identify
self-care goals and barriers, and ensure that the patient's in-home caregivers and
healthcare team remain involved. All patients and CPs will complete quantitative surveys at
baseline, 6, and 12 months. The study will include a mixed-methods approach including
qualitative interviews with patients, CPs and clinicians to evaluate intervention use and
the service's potential for translation. The primary outcome will be HF-related quality of
life at 12 months. Secondary outcomes will include self-care behavior, patient-CP
relationship indicators, hospitalization, and death.
Impact: This study will evaluate a model for leveraging ICGs and structuring their role in
HF patients' overall disease management. If effective, the service may provide the frequent
monitoring and behavior change assistance that patients need, allowing VA to extend its
impact beyond what current care management programs can realistically deliver.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |